Ozden Turel

Ozden Turel

Auto-generated profile, based on publicly available information

Ozden Turel

Department of Pediatric Infectious Diseases, Istanbul Medeniyet University Prof. Dr. Süleyman Yalcın City Hospital, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2013 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
OTOzden Turel
Ozden Turel
SKSultan Kavuncuoglu
Sultan Kavuncuoglu
EHEmine Hosaf
Emine Hosaf
SOSibel Ozbek
Sibel Ozbek
EAEsin Aldemir
Esin Aldemir
RSRengin Siraneci
Rengin Siraneci
We report an outbreak of Achromobacter xylosoxidans at a neonatal intensive care unit. We aimed to present clinical, laboratory and treatment data of the patients. All consecutive episodes of bacteremia due to A. xylosoxidans at our neonatal intensive care unit, beginning with the index case detected at November 2009 until cessation of the outbreak in April 2010, were evaluated retrospectively. Thirty-four episodes of bacteremia occurred in 22 neonates during a 6-month period. Among the affected, 90% were preterm newborns with gestational age of 32 weeks or less and 60% had birth weight of 1000g or less. Endotracheal intubation, intravenous catheter use, total parenteral nutrition and prolonged antibiotic therapy were the predisposing conditions. Presenting features were abdominal distention, thrombocytopenia and neutropenia. The mortality rate was 13.6% and the majority of isolates were susceptible to piperacillin-tazobactam, carbapenems and trimethoprim-sulfametoxazole, and resistant to gentamycin. More than half were breakthrough infections. Despite intensive efforts to control the outbreak by standard methods of hand hygiene, patient screening and isolation, containment could be achieved only after the neonatal intensive care unit was relocated. The investigation was not able to single out the source of the outbreak. A. xylosoxidans has the potential to cause serious infections in premature babies. More studies are needed to determine the importance of different sources of infection in hospital units.

7 February 2022 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
DCDilek Yilmaz Ciftdogan
Dilek Yilmaz Ciftdogan
YKYıldız Ekemen keleş
Yıldız Ekemen keleş
BCBenhur Sirvan Cetin
Benhur Sirvan Cetin
NKNazan Dalgic Karabulut
Nazan Dalgic Karabulut
MEMelike Emiroglu
Melike Emiroglu
AKAteş Kara
Ateş Kara

4 June 2020 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
CYCan Yilmaz Yozgat
Can Yilmaz Yozgat
SUSelcuk Uzuner
Selcuk Uzuner
BDBurcu Bursal Duramaz
Burcu Bursal Duramaz
YYYilmaz Yozgat
Yilmaz Yozgat
UEUfuk Erenberk
Ufuk Erenberk
OTOzden Turel
Ozden Turel

9 November 2012 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
MBMustafa Bakır
Mustafa Bakır
ÖTÖzden Türel
Özden Türel
OTOleksandr Topachevskyi
Oleksandr Topachevskyi
Background: Streptococcus pneumoniaeinfections, which place a considerable burden on healthcare resources, can be reduced in a cost-effective manner using a 7-valent pneumococcal conjugate vaccine (PCV-7). We compare the cost effectiveness of a 13-valent PCV (PCV-13) and a 10-valent pneumococcal non-typeableHaemophilus influenzaeprotein D conjugate vaccine (PHiD-CV) with that of PCV-7 in Turkey.Methods: A cost-utility analysis was conducted and a decision analytical model was used to estimate the proportion of the Turkish population <10 years old that would experience 10 mutually exclusive outcomes over the course of 1 year from a perspective of a healthcare system. Model outcomes were adjusted according to the population demographics and region-specific serotype distribution in Turkey. Health outcomes and direct healthcare costs were simulated for PCV-7, PCV-13 and PHiD-CV.Results: PCV-13 and PHiD-CV are projected to have a substantial impact on pneumococcal disease in Turkey versus PCV-7, with 2,223 and 3,156 quality-adjusted life years (QALYs) and 2,146 and 2,081 life years, respectively, being saved under a 3+1 schedule. Projections of direct medical costs showed that a PHiD-CV vaccination programme would provide the greatest cost savings, offering additional savings of US$11,718,813 versus PCV-7 and US$8,235,010 versus PCV-13. Probabilistic sensitivity analysis showed that PHiD-CV dominated PCV-13 in terms of QALYs gained and cost savings in 58.3% of simulations.Conclusion: Under the modeled conditions, PHiD-CV would provide the most cost-effective intervention for reducing pneumococcal disease in Turkish children.

1 March 2019 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Closed access
OTOzden Turel
Ozden Turel
SMSemih L. Mirapoglu
Semih L. Mirapoglu
MYMine Yuksel
Mine Yuksel
ACAysenur Ceylan
Aysenur Ceylan
BGBilge Sumbul Gultepe
Bilge Sumbul Gultepe

15 May 2020 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
BDBurcu Bursal Duramaz
Burcu Bursal Duramaz
CYCan Yilmaz Yozgat
Can Yilmaz Yozgat
YYYilmaz Yozgat
Yilmaz Yozgat
OTOzden Turel
Ozden Turel
Click on the article title to read more.